Novel small molecule kras inhibitor: drugging undruggable targets for cancer therapeutics

Abstract

The present invention discloses a anticancer activity exhibiting compound of structural formula I: or a pharmaceutically acceptable salt thereof; in which W is selected from a group comprising of substituted saturated/unsaturated branched/linear aliphatic amine, substituted aromatic amine, unsubstituted saturated/unsaturated branched/linear aliphatic amine, unsubstituted aromatic amine; X is selected from a group comprising of H, substituted/unsubstituted saturated/unsaturated branched/linear aliphatic alkyl group with at least one carbon atom, substituted/unsubstituted saturated/unsaturated branched/linear aliphatic alkoxy group with at least one carbon atom, substituted/unsubstituted aryl group, substituted/unsubstituted aryloxy group; Y is selected from a group comprising of H, substituted/unsubstituted saturated/unsaturated branched/linear aliphatic alkyl group bonded to a carbonyl group, substituted/unsubstituted aryl group bonded to a carbonyl group; Z is selected from a group comprising of H, OH.

Dependencies are inferred from the claim text.